Welcome to our dedicated page for AIKI news (Ticker: aiki), a resource for investors and traders seeking the latest updates and insights on AIKI stock.
AIkido Pharma Inc. (AIKI), a biotechnology innovator since 1967, develops targeted cancer treatments and broad-spectrum antiviral therapies through academic collaborations. This page aggregates official announcements and analysis-worthy developments for stakeholders tracking the company's progress.
Access timely updates on clinical milestones, strategic partnerships with leading research institutions, and corporate initiatives like the active share repurchase program. Key focus areas include pancreatic cancer therapies, leukemia treatments, and novel antiviral platforms addressing multiple infectious diseases.
Regularly updated content covers licensing agreements, preclinical results, financial disclosures, and market expansion efforts. Bookmark this page to efficiently monitor AIkido Pharma's evolving role in oncology and virology research without navigating multiple sources.
AIkido Pharma Inc. (NASDAQ: AIKI) announced the successful IPO of ASP Isotopes (NASDAQ: ASPI) on November 10, 2022. The company priced 1,250,000 shares at $4.00 each, raising approximately $5.0 million in gross proceeds. The offering closed on November 14, 2022, enabling ASP Isotopes to enhance capital access and investor visibility. AIkido's CEO, Anthony Hayes, congratulated ASP Isotopes on this accomplishment, emphasizing the challenges faced in public markets. AIkido, established in 1967, focuses on developing anticancer and antiviral therapeutics through partnerships with notable universities.
AIkido Pharma Inc. (Nasdaq: AIKI) announced an update on its share repurchase program, initially authorized on January 21, 2022. On October 5, 2022, the company purchased 10,500 shares at $7.0679 each. Continued repurchases will depend on market conditions and regulatory restrictions. AIkido focuses on developing small-molecule anticancer and antiviral therapeutics, with ongoing partnerships with prominent universities.
AIkido Pharma Inc. (NASDAQ: AIKI) announced an update on its share repurchase program, which was authorized on January 21, 2022. On October 4, 2022, the company repurchased 38,035 shares at $6.99 each. CEO Anthony Hayes emphasized that the repurchase aims to enhance shareholder value by reducing outstanding shares. Future repurchases will occur based on market conditions and regulatory limitations. AIkido Pharma is focused on developing small-molecule therapeutics for cancers and viruses through collaborations with prominent universities.
AIkido Pharma Inc. (Nasdaq: AIKI) announced the continuation of its share repurchase program, initially authorized on January 21, 2022. On October 3, 2022, the company purchased 45,000 shares of common stock at $6.98 per share. Future repurchases will depend on market conditions and regulatory limitations. AIkido focuses on developing anticancer and antiviral therapeutics, leveraging patented technology and collaborations with leading universities.
AIkido Pharma Inc. (Nasdaq: AIKI) has announced an update on its $3 million share repurchase program initiated on January 21, 2022. As of September 30, 2022, the company acquired 41,096 shares at $7.1034 per share. CEO Anthony Hayes highlighted that the stock price remains below book value, reaffirming the board's confidence in the company's future plans. The repurchase strategy will continue based on market conditions and regulatory factors.
AIkido Pharma Inc. (NASDAQ: AIKI) has updated its $3 million Share Repurchase Program, initially authorized on January 21, 2022. As of September 29, 2022, the company has repurchased 303,886 common shares at prices ranging from $5.34 to $6.97. The company plans to continue repurchases based on market conditions and regulatory limitations. AIkido is focused on developing therapeutics for cancer and viral infections through partnerships with major universities, aiming to address unmet medical needs.
Dominari Financial, Inc., a subsidiary of AIkido Pharma, has entered into an exclusive agreement to acquire a broker-dealer firm, marking its first acquisition since its launch in June 2022. This strategic move is aimed at accelerating Dominari's growth in the financial services sector, particularly targeting ultra-high-net-worth investors through a roll-up strategy. Once approved by FINRA, the acquisition will enable Dominari to offer banking and lending services, enhancing its infrastructure and technology to scale rapidly.
AIkido Pharma Inc. (Nasdaq: AIKI) announced on August 9, 2022 that it received an unsolicited acquisition offer from Mr. Shalom Auerbach to buy all of its outstanding common stock at $8.00 per share in cash. The Board of Directors will thoroughly evaluate this proposal to determine the best course of action for the company and its shareholders. Shareholders are advised to take no action at this time. AIkido Pharma, established in 1967, is focused on developing small-molecule therapeutics for cancer and viral infections.
AIkido Pharma Inc. (NASDAQ: AIKI) announced the appointment of Carlos Aldavero as President of its new financial services subsidiary, Dominari Financial, on July 22, 2022. Aldavero previously managed a major business unit at Morgan Stanley, bringing extensive experience in financial services. His role involves acquiring strategic assets in fintech and building a strong management team to drive the subsidiary's growth. This move aims to diversify AIkido's operations beyond biotechnology, potentially reducing volatility and enhancing revenue for shareholders.
AIkido Pharma Inc. (Nasdaq: AIKI) announced on June 23, 2022, that it has regained compliance with NASDAQ's minimum bid price requirement of $1.00 for continued listing. The Company met this requirement when its common stock's closing bid price remained at or above $1.00 for 10 consecutive business days. This compliance matter is now closed, allowing AIkido to continue its operations on the NASDAQ Capital Market without the threat of delisting.
FAQ
What is the market cap of AIKI (aiki)?
